Jasper Therapeutics, Inc. (NASDAQ:JSPR) Stock Has Consensus Price Target of $7.33

Jasper Therapeutics, Inc. (NASDAQ:JSPR) has earned an average rating of “Hold” from the eight research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $7.33.

A number of analysts have recently weighed in on JSPR shares. Piper Sandler began coverage on Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 price objective on the stock. Wall Street Zen lowered Jasper Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, September 19th. HC Wainwright reiterated a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. William Blair began coverage on Jasper Therapeutics in a research note on Wednesday. They set an “outperform” rating for the company. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a report on Friday, July 17th.

Jasper Therapeutics Stock Performance

Shares of JSPR stock opened at $0.48 on Tuesday. Jasper Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $2.69. The company has a 50 day moving average price of $0.66 and a 200 day moving average price of $0.69. The stock has a market capitalization of $15.97 million, a P/E ratio of -0.30 and a beta of 3.16.

Jasper Therapeutics (NASDAQ:JSPR) last announced its earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. On average, research analysts forecast that Jasper Therapeutics will post -0.94 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.